knowledge -WSS

knowledge

author：fashion 2025-10-06 17:21:21 Page View：27

Editor’s note: A recording of the event is embedded below.

Several biosimilar versions of Humira, which for years has been the world’s best-selling medicine, entered the U.S. market over the past year. What has that meant for insurance coverage and the way drugmakers are marketing these medicines? Join leading experts to discuss the impact on the industry and patients.

Sponsor introduction

Thomas Newcomer, vice president and head of U.S. market access, Samsung Bioepis (sponsor)

Featured speakers

Chris M. Brown, president, McAteer
Michael Gonzales, independent health care consultant, Michael Gonzales, LLC; former national and regional account director, AbbVie
Fran Gregory, MBA, PharmD, vice president of emerging therapies, Cardinal Health
Ed Silverman, Pharmalot columnist, senior writer, STAT (moderator)

Sponsored By

Previous article： The world needs the new pandemic treaty
Next article： DIEP, the 'gold standard' of breast reconstruction, is under threat

leisure time

United colonoscopy coverage change 'may cost lives,' doctors say

AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

How Vertex's cystic fibrosis drug is changing patients' lives

SusanUlan,right,greetshergranddaughterIvy,andherdaughterJessieAnderson,atAnderson'shome.SuzanneKreit

Cancer drug shortages should be causing more outrage

DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

U.S. death rates show how politics are affecting public health

DrewAngerer/GettyImagesInanidealworld,publichealthwouldbeindependentofpolitics.YetrecenteventsintheU